Results 51 to 60 of about 20,522 (204)

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 10961-10976, December 2026.
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest   +3 more
wiley   +1 more source

Effect of ezetimibe on blood lipids.

open access: yes, 2015
Semi-fasted blood lipid levels of obese hyperlipidemic hamsters treated for 14 days with vehicle (PO, QD) or Ezetimibe (10.0 mg/kg, PO, QD).
Louise S. Dalbøge (420563)   +6 more
core   +1 more source

Cryo-EM structures of NPC1L1 reveal mechanisms of cholesterol transport and ezetimibe inhibition

open access: yes, 2020
The intestinal absorption of cholesterol is mediated by a multipass membrane protein, Niemann-Pick C1-Like 1 (NPC1L1), the molecular target of a cholesterol lowering therapy ezetimibe. While ezetimibe gained Food and Drug Administration approval in 2002,
Huang, Ching-Shin   +9 more
core   +1 more source

Cholesterol Biomimetic Fluorescent Probe for the High Signal‐to‐Noise Ratio and Selectivity Imaging of Nonalcoholic Fatty Liver

open access: yesAggregate, Volume 7, Issue 11, November 2026.
A cholesterol‐biomimetic AIE probe, TPAS‐PyCHO+, was designed and synthesized for selective imaging of nonalcoholic fatty liver. The probe hijacked NPC1L1‐mediated clathrin‐dependent endocytosis in steatotic hepatocytes, selectively accumulated in lipid droplets, and enabled high signal‐to‐noise ratio imaging of NAFLD in mice.
Kunyi Wang   +7 more
wiley   +1 more source

Niacin or Ezetimibe for Patients with, or at Risk of Coronary Heart Disease

open access: yes, 2010
Coronary heart disease treatment with HMG-CoA reductase inhibitors has been very successful. There is increasing interest in adding other lipid lowering therapy, primarily as additional therapy onto HMG-CoA reductase therapy.
Robert Guthrie
core   +1 more source

EZETIMIBE IN HYPERCHOLESTEROLAEMIA

open access: yesInternational Journal of Clinical Practice, 2002
SUMMARYEzetimibe is the first member of a new class of selective cholesterol absorption inhibitors, compounds that effectively block intestinal absorption of dietary and biliary cholesterol, without affecting absorption of fat soluble vitamins or triglycerides.
openaire   +2 more sources

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3862-3873, November 2026.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu   +7 more
wiley   +1 more source

Ezetimibe inhibits expression of acid sphingomyelinase in liver and intestine

open access: yes, 2009
Ezetimibe inhibits cholesterol absorption in the intestine. Sphingomyelin has strong interactions with cholesterol. We investigated the effects of ezetimibe on Sphingomyelinase (SMase) expression in intestine and liver. After feeding rats with ezetimibe (
Wu, Jun   +19 more
core   +1 more source

In Silico Clinical Trials in Drug Development: Virtual Patients, Applications, and Regulatory Convergence

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1181-1194, November 2026.
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus   +7 more
wiley   +1 more source

Efficient and scalable process for the synthesis of antihypercholesterolemic drug ezetimibe

open access: yes, 2016
An efficient and scalable process for the synthesis of antihypercholesterolemic drug ezetimibe through chiral Evans auxiliary (S)-4-phenyl-2-oxazolidinone is described.
Yijun Zhu (2975739)   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy